MRK - Merck & Co., Inc.

NYSE - NYSE Delayed price. Currency in USD
59.41
-0.22 (-0.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close59.63
Open59.82
Bid58.85 x 500
Ask59.99 x 100
Day's range59.11 - 60.08
52-week range52.83 - 66.41
Volume13,500,074
Avg. volume12,870,472
Market cap159.974B
Beta1.11
PE ratio (TTM)68.29
EPS (TTM)0.87
Earnings date1 May 2018
Forward dividend & yield1.92 (3.22%)
Ex-dividend date2018-03-14
1y target est68.40
Trade prices are not sourced from all markets
  • Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast
    Market Realist12 hours ago

    Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast

    AbbVie (ABBV) released its 1Q18 earnings results for the quarter that ended on March 31 today. The company posted net revenues of $7.93 billion, representing YoY (year-over-year) revenue growth of ~21.4%. The reported revenue exceeded analysts’ estimates of $7.59 billion.

  • Bristol's Case for Opdivo Optimism Has Shaky Foundations
    Bloomberg14 hours ago

    Bristol's Case for Opdivo Optimism Has Shaky Foundations

    A lot has to go right for it to fend off Merck’s surging Keytruda.

  • How Analysts Rate JNJ after 1Q18 Earnings
    Market Realist18 hours ago

    How Analysts Rate JNJ after 1Q18 Earnings

    As discussed earlier, Johnson & Johnson reported a 12.6% increase in revenues to $20.0 million in 1Q18 as compared to $17.8 million in 1Q17. The increase included 8.4% growth in revenues at constant exchange rates and a 4.2% positive impact of foreign exchange.

  • Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates
    Market Realist18 hours ago

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb (BMY) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues in 1Q18. It reported EPS of $0.94 on revenues of $5.2 billion in 1Q18 today, compared to analysts’ estimates for EPS of $0.85 on revenues of $5.2 billion.

  • Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
    Zacks19 hours ago

    Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?

    With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.

  • What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?
    Market Realist19 hours ago

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    As discussed earlier, Johnson & Johnson (JNJ) reported revenue growth of 12.6% in its 1Q18 revenues to $20.0 billion.

  • Bristol-Myers' cancer drug Opdivo fuels growth, but revenue falls short
    CNBC21 hours ago

    Bristol-Myers' cancer drug Opdivo fuels growth, but revenue falls short

    Bristol-Myers Squibb posted mixed first-quarter results and boosted its full-year forecast.

  • Business Insider UK2 days ago

    U.S. court upholds dismissal of $200 million Merck verdict against Gilead

    The U.S. Court of Appeals for the Federal Circuit upheld a June 2016 ruling that the two Merck patents, which cover methods of treating Hepatitis C, were unenforceable because of a pattern of misconduct by the company, including lying under oath by one of its in-house lawyers. Merck did not immediately provide a comment on the decision. A jury in federal court in San Jose, California, awarded Merck $200 million in March 2016 after finding Sovaldi and Harvoni infringed two of its patents.

  • Business Insider UK2 days ago

    U.S. court upholds dismissal of $200 million Merck verdict against Gilead

    The U.S. Court of Appeals for the Federal Circuit upheld a June 2016 ruling that the two Merck patents, which cover methods of treating Hepatitis C, were unenforceable because of a pattern of misconduct by the company, including lying under oath by one of its in-house lawyers. Merck did not immediately provide a comment on the decision. A jury in federal court in San Jose, California, awarded Merck $200 million in March 2016 after finding Sovaldi and Harvoni infringed two of its patents.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realist2 days ago

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • Analysts’ Estimates for Sanofi’s 1Q18 Earnings
    Market Realist2 days ago

    Analysts’ Estimates for Sanofi’s 1Q18 Earnings

    Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.

  • Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
    Market Realist2 days ago

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist2 days ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
    Market Realist2 days ago

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.

  • Why Incyte Stock Fell ~9% on April 24
    Market Realist2 days ago

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • What's in the Cards for Merck (MRK) This Earnings Season?
    Zacks2 days ago

    What's in the Cards for Merck (MRK) This Earnings Season?

    Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

  • Gilead Sciences Focuses on Its Liver Disease Portfolio
    Market Realist2 days ago

    Gilead Sciences Focuses on Its Liver Disease Portfolio

    By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist3 days ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
    Motley Fool3 days ago

    Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma

    It's a lot easier to be patient once those quarterly payments start adding up.

  • Henry Schein to Merge Animal Health with Vets First Choice
    Market Realist3 days ago

    Henry Schein to Merge Animal Health with Vets First Choice

    On April 23, Henry Schein (HSIC) announced its plans to spin off and merge its animal health business with Vets First Choice to form a joint venture, Vets First Corp., aimed to advance animal healthcare and benefit veterinarians, pets, product manufacturers, and pet owners. Henry Schein, one of the world’s largest global supply chain providers of animal health products, has established a top market position in North America, Europe, Australia, and New Zealand.

  • Business Wire3 days ago

    European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial

    KENILWORTH, N.J.--(BUSINESSWIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency (EMA), the centralized ...

  • Business Wire3 days ago

    European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial

    Merck , known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency , the centralized review process has begun for the company’s Type II Variation, which seeks approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous ...

  • MarketWatch4 days ago

    Merck's stock surges to lead Dow's gainers after Goldman turns bullish

    Shares of Merck & Co. Inc. ran up $1.61, or 2.7%, to a near three-month high in afternoon trade Monday, enough to pace the Dow Jones Industrial Average's gainers, after Goldman Sachs turned bullish on ...

  • Merck Gets Another Upgrade Thanks To Keytruda
    Investing.com2 days ago

    Merck Gets Another Upgrade Thanks To Keytruda

    Investing.com - Goldman Sachs (NYSE:GS) is the latest Wall Street firm to upgrade Merck (NYSE:MRK) because of the blockbuster potential of its cancer drug Keytruda.The firm upgraded Merck from neutral to buy, while adding it to its list of favorite stocks. In a note to clients, Morgan Stanley (NYSE:MS) said Keytruda sales, which doubled to $3.8 billion in 2017, could soar to $16 billion by 2025.Keytruda is widely expected to gain a larger share of the market for non-small cell lung cancers. It's currently approved for lung, skin and stomach cancers, and is being tested for still others. Morgan Stanley, Barclays (LON:BARC) and Leerick Partnters have all recently upgraded the stock and/or raised their price targets. Merck shares, however, are down 5% over the past 12 months.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes